Stock comparison
Harmony Biosciences Holdings
STERIS
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
STE
STERIS
Market cap
$21.26B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | STE | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 53C | HRMY |
| Benjamin Graham | 60C | 68B | STE |
| Philip Fisher | 75B | 58C | HRMY |
| Peter Lynch | 62C | 52C | HRMY |
| Joel Greenblatt | 28F | 35D | STE |
| Charlie Munger | 62C | 42D | HRMY |
| Terry Smith | 67B | 48D | HRMY |
Side-by-side metrics
| Metric | HRMY | STE |
|---|---|---|
| Market cap | $1.75B | $21.26B |
| P/E (TTM) | 11.8x | 25.3x |
| EV/EBIT | 6.4x | 17.7x |
| ROIC (TTM) | 12.5% | 8.51% |
| Gross margin | 76.55% | 44.25% |
| Net margin | 16.2% | 13.18% |
| Revenue CAGR 5y | 29.85% | 8.88% |
| EPS CAGR 5y | 46.45% | 33.45% |
| Debt / Equity | 0.2x | 0.0x |
| Dividend yield | 0.0% | 1.22% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- Revenue CAGR 5y29.85%vs 8.88%+70%
- EV/EBIT6.4xvs 17.7x+64%
- P/E (TTM)11.8xvs 25.3x+53%
- Gross margin76.55%vs 44.25%+42%
STE leads on
- Dividend yield1.22%vs 0.0%+100%
- Debt / Equity0.0xvs 0.2x+93%
- Market cap$21.26Bvs $1.75B+92%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.